TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02314949

Intervention type: PROCEDURE
Intervention: intestinal transplantation
Study: NCT00719758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP (BERASUS LA)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120 (Kremezin®)
Description: oral
Study: NCT05152004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pariet
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pariet
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolin
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amolin
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid
Description: Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
Study: NCT00731601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: pantoprazole 40 mg/q6h IV infusion for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 8 mg/h IV infusion for three days
Study: NCT04149769

Intervention type: DEVICE
Group type: OTHER
Intervention: Indego Exoskeleton
Description: Regular dosing of Indego Exoskeleton walking.
Study: NCT02298595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: XXXX day 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: XXXX day 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: XXXX day 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: 200, 250, 300, or 350 mg/day by mouth every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: 200, 250, 300, or 350 mg/day by mouth every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: 200, 250, 300, or 350 mg/day by mouth every day
Study: NCT03771768

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diode laser 980nm&100 mWatt
Description: Diode laser 980 nm \&100 milli Watt.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 0.1 \&5gm paste 4 times/day
Study: NCT02490527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pure epicatechin capsules (50mg)
Description: Epicatechin is a compound found naturally in dark chocolate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin (40mg)
Description: A cholesterol-lowering medication that blocks the production of cholesterol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin (40mg)
Description: A cholesterol-lowering medication that blocks the production of cholesterol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect and will act as a control.
Study: NCT02093468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MST-188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MST-188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00713622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
Study: NCT02379650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04280939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
Study: NCT03554122

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients spinal injections were performed without Shotblocker
Study: NCT00460512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
Study: NCT04280939

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
Study: NCT01291069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil Citrate
Description: If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
Study: NCT02639195

Intervention type: OTHER
Intervention: Treatment
Description: Retrospective chart review of patients treated with manual therapy.
Study: NCT01479556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg BID p.o.
Study: NCT00898742

Intervention type: GENETIC
Intervention: DNA and tissue microarray analysis
Description: The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.

Intervention type: OTHER
Intervention: mass spectrometry
Description: The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
Study: NCT01892605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music listening
Description: The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
Study: NCT00764244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal triamcinolone injections
Description: Intravitreal triamcinolone injections

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Laser photocoagulation
Study: NCT04245930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bovine Pericardial Patch in Immediate Implant Breast Reconstruction
Description: Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction
Description: Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
Study: NCT04577144

Intervention type: OTHER
Intervention: Online survey only
Description: There are no interventions planned for this study. This is an observational study only.
Study: NCT02177344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Ipratropium bromide
Description: One puff, 4 times daily by oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Ipratropium bromide
Description: One puff, 4 times daily by oral inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent
Description: Two puffs, 4 times daily by oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00824681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Of Family Together (S.O.F.T.) Music Program
Description: Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
Study: NCT02256319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
Study: NCT00824681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Therapy Related Activities (NTRA)
Description: NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
Study: NCT02447731

Intervention type: DEVICE
Intervention: Induction of sound waves in lungs by sonic oscillator
Description: A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
Study: NCT00126048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT03136068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Trans-abdominal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Trans-abdominal injection
Study: NCT01183091

Intervention type: PROCEDURE
Intervention: Ablation of atrial fibrillation
Description: Ablation of atrial fibrillation
Study: NCT00432380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: oral doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: oral doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral dose
Study: NCT01105533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
Study: NCT02950415

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: virtual
Description: Parent is present via an internet pad (iPad)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: virtual
Description: Parent is present via an internet pad (iPad)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: coaching
Description: Parent learns what to say verbally to soothe child

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: coaching
Description: Parent learns what to say verbally to soothe child

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: physical
Description: Parent is present in the operating room

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: physical
Description: Parent is present in the operating room

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no coaching
Description: Parent does not learn what to say verbally to soothe child

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no coaching
Description: Parent does not learn what to say verbally to soothe child
Study: NCT03910400

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computation of quantitative flow ratio
Description: After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computation of quantitative flow ratio
Description: After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
Study: NCT01105533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 1mg Capsule Once Daily (Dose Escalation) Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 2mg Capsule Once Daily (Dose Escalation) Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 4mg Capsule Once Daily (Dose Escalation) Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 6mg Capsule Once Daily (Dose Escalation) Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 9mg Capsule Once Daily (Dose Escalation) Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 8mg Capsule Once Daily (Dose Escalation) Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 4mg Capsule Twice Daily (Dose Escalation) Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 6mg Capsule Twice Daily (Dose Escalation) Continuous
Study: NCT02256319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
Study: NCT03909373

Intervention type: OTHER
Intervention: PSFS
Description: Patients will complete the patient specific functional scale. no intervention being administered
Study: NCT04457531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiuWeiLuoBi Granule
Description: LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
Study: NCT01261429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasigna
Description: The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes.
Study: NCT04093479

Intervention type: OTHER
Intervention: blood samples
Description: blood samples will be taken repeatedly
Study: NCT02173301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP23829 400 mg QD
Description: active dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP 23829 800 mg QD
Description: active dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP23829 400 mg BID
Description: active dose 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control
Study: NCT04557982

Intervention type: PROCEDURE
Intervention: A painful procedure (peripheral venepuncture)
Description: The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.

Intervention type: PROCEDURE
Intervention: A painful procedure (peripheral venepuncture)
Description: The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.

Intervention type: PROCEDURE
Intervention: A painful procedure (peripheral venepuncture)
Description: The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
Study: NCT03535506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
Study: NCT03078530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a pill with inactive ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: This is a probiotic mixture available to randomized study participants, starting with subject 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: This is a probiotic mixture available to the first 28 subjects randomized to the study
Study: NCT02858167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
Study: NCT05785416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)
Description: PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Description: The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
Study: NCT03120520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo